688298 东方生物
2024/09 - 九个月2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-3.662-5.09827.533105.7741.240
总资产报酬率 ROA (%)-3.043-4.03621.01378.40885.259
投入资产回报率 ROIC (%)-3.358-4.61325.748101.22753.596

边际利润分析
销售毛利率 (%)34.69143.01150.79373.79079.243
营业利润率 (%)-42.965-46.80028.83556.80360.463
息税前利润/营业总收入 (%)-49.209-82.88821.29957.40162.231
净利润/营业总收入 (%)-41.700-50.99923.92248.58551.459

收益指标分析
经营活动净收益/利润总额(%)128.97445.059149.748100.555104.276
价值变动净收益/利润总额(%)-30.940-8.1700.3110.1940.760
营业外收支净额/利润总额(%)-1.7505.045-2.326-0.111-0.003

偿债能力分析
流动比率 (X)4.0945.4303.8393.9482.982
速动比率 (X)3.7105.1113.6503.7192.639
资产负债率 (%)14.36916.07622.24223.26231.395
带息债务/全部投入资本 (%)7.1787.7529.8400.899--
股东权益/带息债务 (%)1,280.3521,180.349910.40610,972.267771.875
股东权益/负债合计 (%)581.518514.172342.869328.380218.044
利息保障倍数 (X)7.0472.467-3.09686.81335.163

营运能力分析
应收账款周转天数 (天)97.966113.14130.66632.0420.000
存货周转天数 (天)243.305299.88137.65257.5480.000